Filing Flows › AbCellera Biologics (ABCL) › Q3 2025
AbCellera Biologics (ABCL) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
AbCellera Biologics (ABCL) reported revenue of $9.0M for the third quarter 2025 (Q3 2025), +38% from a year earlier and -48% from the quarter before. Operating margin was -851.8%, net loss $57.1M (637.8% of revenue).
AbCellera Biologics, Q3 2025: revenue $9.0M (+38% year over year), operating margin -851.8%, net loss $57.1M, operating cash flow −$52.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.0M | -48% | +38% |
| Operating profit | −$76.3M | — | — |
| Net earnings | −$57.1M | — | — |
| Operating cash flow | −$52.6M | — | — |
What changed
Revenue was $9.0M in Q3 2025, up 38% year over year and down 48% from the previous quarter. Research fees was the largest line at 98% of revenue. Research fees added $2.5M year over year (up 40%), 103% of the total change. Licensing revenue declined 37%.
Operating costs exceeded revenue by $76.3M, an operating margin of -851.8%. Total costs fell 15% while revenue rose 38%. The fastest-growing cost line was Research & development (+34%). The quarter ended with a net loss of $57.1M, wider than the previous quarter's $34.7M loss.
Operating cash flow was −$52.6M. Non-cash charges added back $5.2M of depreciation and amortization and $13.9M of share-based compensation. Working capital and other items used $14.6M. Capital expenditures of $8.9M exceeded it, leaving free cash flow of −$61.5M.
Questions
What was AbCellera Biologics' revenue in the third quarter 2025?
AbCellera Biologics (ABCL) reported revenue of $9.0M for the third quarter 2025 (Q3 2025), +38% from a year earlier and -48% from the quarter before.
Was AbCellera Biologics profitable in the third quarter 2025?
Operating loss was $76.3M (-851.8% of revenue) and net loss $57.1M.